Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALGeneric

EVOCLIN

CLINDAMYCIN PHOSPHATE

Standard Dose
1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview EVOCLIN is listed in Drugs@FDA under application 050801 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CLINDAMYCIN PHOSPHATE Form and strength AEROSOL, FOAM;TOPICAL - 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NORVIUM BIOSCIENCE Submission history Latest submission status date: 2018-04-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview EVOCLIN is listed in Drugs@FDA under application 050801 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CLINDAMYCIN PHOSPHATE Form and strength AEROSOL, FOAM;TOPICAL - 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NORVIUM BIOSCIENCE Submission history Latest submission status date: 2018-04-17 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
EVOCLIN (CLINDAMYCIN PHOSPHATE) | Drug Monograph | MedicHelpline